Buenos Aires, Argentina (UroToday.com) Yves Fradet, Professor University of Laval, discussed imaging in bladder cancer. Particularly advanced imaging such as FDG-PET/CT is being explored as a means to improve detection metastatic disease.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
Prior results have shown sensitivity and specificity to be 27.5% and 94.9% which highlights the positive predictive value of this imaging modality. Costs need to be taken into account and current guidelines caution use of advanced imaging outside of clinical trial setting. Until further data suggest clear superiority over conventional imaging including CT and bone scan in staging patients with MIBC, we need to be extremely cautious prior to over utilizing this expensive technology.
World Urological Oncology Federation Symposium at the SIU Congress 2016 - October 20 - 23, 2016 – Buenos Aires, Argentina
Written By: Stephen B. Williams, M.D., Assistant Professor in Urology, The University of Texas Medical Branch, Galveston, TX. and Ashish Kamat, M.D. Professor, Department of Urology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX.